MUMBAI / RAJKOT - In a regulatory update as submitted to the Indian Stock Exchanges, Mumbai headquartered pharmaceutical products manufacturing Indian company Cipla Ltd said of having expanded partnership with Roche Pharma India Pvt Ltd to further improvise access to key oncology medicines.
In a press-release titled, "Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines", as attached and enclosed with the regulatory filing as submitted by the company to the Indian Bourses, it further read that, Cipla inks a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India.
The release further read that, Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India.
Under this agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs viz.,Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).
Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.
In case, if you wish to VERIFY, the above narrated news-report, please CLICK here.
No comments:
Post a Comment